Review article

the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis

J. L. Damman, E. A. Rodriguez, A. H. Ali, C. W. Buness, K. L. Cox, E. J. Carey, Keith Lindor

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Background and Aims: PSC is an autoimmune biliary inflammatory disorder that is often associated with inflammatory bowel disease (IBD), with 50%-75% of patients with PSC having coexisting IBD, most commonly ulcerative colitis. Currently, no medical therapies have been shown to improve the disease course or slow its progression. However, ongoing research has resulted in a growing interest in the use of antibiotics for treatment of PSC, of which vancomycin is the most studied. In this review, we summarise the current evidence on the use of vancomycin in PSC and comment on future research areas of interest. Methods: A comprehensive PUBMED and EMBASE literature search for articles on vancomycin, PSC, therapeutic options and microbiome was performed. Results: Two randomised clinical trials, three case series and two case reports were included in the study. These include uncontrolled data from at least 98 patients that include promising improvements in biochemistry and imaging. Optimal dosing regimens are unclear. Conclusion: Vancomycin is one of the most studied antibiotics used in the treatment of PSC with promising results. There is not currently sufficient evidence to support treatment recommendations. Further research is needed to establish if vancomycin is a PSC treatment.

Original languageEnglish (US)
Pages (from-to)886-895
Number of pages10
JournalAlimentary Pharmacology and Therapeutics
Volume47
Issue number7
DOIs
StatePublished - Apr 1 2018

Fingerprint

Sclerosing Cholangitis
Vancomycin
Inflammatory Bowel Diseases
Therapeutics
Anti-Bacterial Agents
Microbiota
Ulcerative Colitis
Research
Biochemistry
Randomized Controlled Trials

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Review article : the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis. / Damman, J. L.; Rodriguez, E. A.; Ali, A. H.; Buness, C. W.; Cox, K. L.; Carey, E. J.; Lindor, Keith.

In: Alimentary Pharmacology and Therapeutics, Vol. 47, No. 7, 01.04.2018, p. 886-895.

Research output: Contribution to journalReview article

Damman, J. L. ; Rodriguez, E. A. ; Ali, A. H. ; Buness, C. W. ; Cox, K. L. ; Carey, E. J. ; Lindor, Keith. / Review article : the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis. In: Alimentary Pharmacology and Therapeutics. 2018 ; Vol. 47, No. 7. pp. 886-895.
@article{b5ffa34151984f05ace21d55ac94c221,
title = "Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis",
abstract = "Background and Aims: PSC is an autoimmune biliary inflammatory disorder that is often associated with inflammatory bowel disease (IBD), with 50{\%}-75{\%} of patients with PSC having coexisting IBD, most commonly ulcerative colitis. Currently, no medical therapies have been shown to improve the disease course or slow its progression. However, ongoing research has resulted in a growing interest in the use of antibiotics for treatment of PSC, of which vancomycin is the most studied. In this review, we summarise the current evidence on the use of vancomycin in PSC and comment on future research areas of interest. Methods: A comprehensive PUBMED and EMBASE literature search for articles on vancomycin, PSC, therapeutic options and microbiome was performed. Results: Two randomised clinical trials, three case series and two case reports were included in the study. These include uncontrolled data from at least 98 patients that include promising improvements in biochemistry and imaging. Optimal dosing regimens are unclear. Conclusion: Vancomycin is one of the most studied antibiotics used in the treatment of PSC with promising results. There is not currently sufficient evidence to support treatment recommendations. Further research is needed to establish if vancomycin is a PSC treatment.",
author = "Damman, {J. L.} and Rodriguez, {E. A.} and Ali, {A. H.} and Buness, {C. W.} and Cox, {K. L.} and Carey, {E. J.} and Keith Lindor",
year = "2018",
month = "4",
day = "1",
doi = "10.1111/apt.14540",
language = "English (US)",
volume = "47",
pages = "886--895",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Review article

T2 - the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis

AU - Damman, J. L.

AU - Rodriguez, E. A.

AU - Ali, A. H.

AU - Buness, C. W.

AU - Cox, K. L.

AU - Carey, E. J.

AU - Lindor, Keith

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background and Aims: PSC is an autoimmune biliary inflammatory disorder that is often associated with inflammatory bowel disease (IBD), with 50%-75% of patients with PSC having coexisting IBD, most commonly ulcerative colitis. Currently, no medical therapies have been shown to improve the disease course or slow its progression. However, ongoing research has resulted in a growing interest in the use of antibiotics for treatment of PSC, of which vancomycin is the most studied. In this review, we summarise the current evidence on the use of vancomycin in PSC and comment on future research areas of interest. Methods: A comprehensive PUBMED and EMBASE literature search for articles on vancomycin, PSC, therapeutic options and microbiome was performed. Results: Two randomised clinical trials, three case series and two case reports were included in the study. These include uncontrolled data from at least 98 patients that include promising improvements in biochemistry and imaging. Optimal dosing regimens are unclear. Conclusion: Vancomycin is one of the most studied antibiotics used in the treatment of PSC with promising results. There is not currently sufficient evidence to support treatment recommendations. Further research is needed to establish if vancomycin is a PSC treatment.

AB - Background and Aims: PSC is an autoimmune biliary inflammatory disorder that is often associated with inflammatory bowel disease (IBD), with 50%-75% of patients with PSC having coexisting IBD, most commonly ulcerative colitis. Currently, no medical therapies have been shown to improve the disease course or slow its progression. However, ongoing research has resulted in a growing interest in the use of antibiotics for treatment of PSC, of which vancomycin is the most studied. In this review, we summarise the current evidence on the use of vancomycin in PSC and comment on future research areas of interest. Methods: A comprehensive PUBMED and EMBASE literature search for articles on vancomycin, PSC, therapeutic options and microbiome was performed. Results: Two randomised clinical trials, three case series and two case reports were included in the study. These include uncontrolled data from at least 98 patients that include promising improvements in biochemistry and imaging. Optimal dosing regimens are unclear. Conclusion: Vancomycin is one of the most studied antibiotics used in the treatment of PSC with promising results. There is not currently sufficient evidence to support treatment recommendations. Further research is needed to establish if vancomycin is a PSC treatment.

UR - http://www.scopus.com/inward/record.url?scp=85041629704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041629704&partnerID=8YFLogxK

U2 - 10.1111/apt.14540

DO - 10.1111/apt.14540

M3 - Review article

VL - 47

SP - 886

EP - 895

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 7

ER -